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Abstract
Background: Primary mitochondrial disorders (PMD) are rare conditions resulting in progressive multi-organ failure.
Cardiovascular involvement (CVI) has been reported in paediatric patients. However, its age-related prevalence,
clinical presentation and prognostic impact are unresolved. We detailed CVI in a cohort of children diagnosed with
PMD over two decades at a tertiary referral centre.
Results: We enrolled 86 PMD patients (M/F = 30/56; mean age 6.4 ± 8.58 years). CVI was detected in 31 patients
(36%), with mean age at onset of 5.7 ± 7.8 years including the pre- and neonatal phase in 14, often representing the
first sign of PMD (42% of those with CVI). Heart disease resulted more common in males and in children with
specific aetiologies (Barth, TMEM70 and MELAS syndromes). Hypertrophic, non-compaction and dilated
cardiomyopathies were the prevalent disorders, although pulmonary arterial hypertension was also found. Adverse
cardiac events (heart failure, resuscitated cardiac arrest, ICD/PM implantation, sudden death) occurred in 19% of
children with CVI over a follow-up period of 5.4 ± 4.3 years. All-cause mortality was higher in patients with CVI
compared to those without CVI (45.1% vs 21.8%; p < 0.01); female sex, age at onset < 5 years, acute heart failure at
presentation and diabetes also proved independent predictors of outcome.
Conclusion: Cardiovascular involvement occurred in over one-third of children diagnosed with PMD, often at a very
early age, and was associated with adverse prognosis. Final outcome of PMD-related CVI was influenced by the specific
underlying aetiology, suggesting the need for tailored management of heart failure and sudden death prevention.
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Background
Primary mitochondrial disorders (PMD) comprise a
group of rare genetic disorders characterized by im-
paired energy production due to mutations in nuclear or
mitochondrial genes involved in oxidative phosphoryl-
ation. Organs with high-energy requirements, such as
brain, heart and skeletal muscle, rely heavily on mito-
chondrial function, are more severely affected [1].
Besides the defects in mitochondrial proteins, the im-
pairment of the regulatory pathways at the basis of mito-
chondria homeostasis may lead to mitochondrial
dysfunction, decreased autophagy and neuronal death
[2]. These mechanisms have been proved to be causative
of distinct neurodegenerative disorders and age-related
pathologies, other than being potentially involved in the
maturation of cardiomyocytes [3]. Inducers of mito-
phagy, the process that selectively removes damaged or
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redundant mitochondria, are currently under investiga-
tion as potential therapeutic strategy for mitochondrial
related disorders [4].
Cardiovascular involvement (CVI) has been described
in PMD [5, 6]); however, its age-related prevalence, clin-
ical presentation and prognostic impact are still incom-
pletely resolved. Specifically, whether the outcome of
CVI is comparable across the spectrum of PMD is diffi-
cult to assess due to the rarity and heterogeneity of the
different subsets. The issue bears relevance to individual
management of these children who are categorized
under the same diagnostic umbrella but may have radic-
ally different phenotypes and clinical outcome. Aim of
this study was to assess CVI over long-term follow-up in
a sizeable cohort of children with PMD extensively char-
acterized and followed over the last two decades at a ter-
tiary referral centre for metabolic disease.
Methods
We retrospectively analysed clinical, biochemical, histo-
logical and genetic records of 86 children diagnosed with
PMD, consecutively evaluated at Anna Meyer Children
Hospital from January 1997 to December 2017. The in-
vestigation conforms to the principles outlined in the
Declaration of Helsinki. Local paediatric ethics commit-
tee at Anna Meyer Children Hospital has approved the
study protocol; written informed consent forms have
been collected from living patients or their relatives.
Diagnosis of primary mitochondrial disorder
Over the last two decades, 365 children have been evalu-
ated for suspected primary mitochondrial disorders: in
86, PMD was diagnosed based on the Modified Walker
Criteria [7]. Clinical and laboratory assessment at base-
line is described in Table 1. Patients presenting charac-
teristic phenotypes (i.e. MELAS syndrome, TMEM70
deficiency, Barth syndrome) were referred for molecular
investigation. In the absence of evocative phenotype,
muscular biopsy for standard histology/ histochemistry,
electron microscopy and mitochondrial enzyme assay
was performed. The standard diagnostic panel included
hematoxylin and eosin, modified Gomori trichrome,
lipid stains, succinate dehydrogenase (SDH), and
cytochrome oxidase enzyme histo-chemistry. Biochem-
ical assays of respiratory chain complex activity were
systematically performed, whereas electron microscopy
was added only in selected cases. If the muscular biopsy
was consistent with underlying mitochondrial disorder,
mt-DNA analysis was performed on leukocytes, myo-
cytes or urinary epithelium. Large deletions-duplications
were documented by Southern Blot or Next Generation
Sequencing. Quantitative real-time PCR quantification
of total mt-DNA content in affected tissues was required
to confirm mitochondrial DNA depletion syndromes; a
reduction in mt-DNA copy number > 60–65% of the
average recorded in age-matched controls confirmed the
diagnosis. In case of negative results despite high clin-
ical/biochemical suspicion, exome sequencing was
considered.
Eight patients with paediatric onset Mitochondrial
myopathy, encephalopathy, lactic acidosis, and stroke
(MELAS) syndrome from the present cohort have
been included in a recent publication addressing car-
diac phenotypes [8] Four patients diagnosed by whole
exome sequencing have been described as isolated
case reports [9–11].
Definition of cardiovascular involvement
All patients were screened for CVI at initial evaluation,
including complete clinical examination, twelve-lead
ECGs and transthoracic echocardiography. M-mode
measurements were indexed to age and body-surface
area and corresponding z-scores were derived. Further
investigations were added as appropriate in patients with
CI, according to clinical status (24-h Holter monitoring,
cardiac catheterization, cardiac magnetic resonance, ex-
ercise test).
Cardiovascular involvement associated with PMD was
defined by one of the following:
– Hypertrophic cardiomyopathy (HCM): septal or left
ventricular (LV) posterior wall thickness over 2 Z
score, in absence of other causative conditions;
– Dilated cardiomyopathy (DCM): increased
ventricular end diastolic inner diameter (> 2 Z
Score) occurring with systolic dysfunction, assessed
on the basis of ejection fraction (EF). EF was
measured trough biplane Simpson method (normal
value > 55%, mild dysfunction 45–54%, moderate
dysfunction 30–44%, severe dysfunction < 30%).
– Non-compaction (NC) phenotype: hyper-
trabeculated aspect of left ventricular walls with end
systolic ratio of non-compacted to compacted layers
over 2; it was considered a pathologic finding only if
associated with previous phenotypes or in presence
of ventricular dysfunction.
– Pulmonary arterial hypertension (PAH): increase in
mean pulmonary arterial pressure (PAPm) ≥25
mmHg at rest as assessed by right heart
catheterization
– Arrhythmic disorders and high-grade atrioventricu-
lar (AV) block (type II second-degree AV block,
third-degree AV block)
Follow-up protocol and study end-points
After initial evaluation, follow-up visits were scheduled at
least every 6months, including clinical examination,
neurologic evaluation and metabolic assessment [Table 1].
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Cardiologic follow-up was planned every 3–6months in
the presence of CVI, otherwise every 12months.
Overt CVI involvement was defined in presence of
clinical signs and/or symptoms (dyspnoea, tachycardia,
hypo- or hypertension, gallop rhythm, cyanosis, hypox-
emia, excessive swelling, feeding difficulties or fatigue
not attributable to neurologic/muscular impairment,
pathologic murmur).
Twenty-four hour Holter monitoring was proposed
in case of pathologic ECG at rest, or in presence of
signs/symptoms suggestive for rhythm anomalies.
Right heart catheterization was performed only in
patients with echocardiographic evidence of pulmon-
ary hypertension.
Major adverse cardiac events (MACEs) were recorded,
including hospitalization for heart failure (HF), death
due to HF, sudden death, resuscitated cardiac arrest,
high-grade AV block, life-threatening arrhythmias and
cardiac transplantation. All cause and cardiac mortality
were assessed.
Statistical analysis
Continuous variables were presented as mean ± standard
deviations and discrete variables are presented as counts
Table 1 Baseline and follow-up assessment of patients diagnosed with Primary Mitochondrial Disorders
Family history • Pattern of transmission (autosomal, X-linked, matrilineal)









Clinical examination • Auxological parameters (weight, length/stature, cranial circumference)
• Vital parameters (blood pressure, heart rate, respiratory rate, oxygen saturation)
• Assessment of neurological status and cognitive development
Specialist evaluations • Audiological screening
• Ophthalmologic screening in order to exclude:
- retinitis
- cataract
- optic nerve atrophy
- progressive loss of vision
Cardiologic evaluation • Clinical examination
• 12-lead ECG and transthoracic echocardiograph
Brain Magnetic Resonance • Common findings:
- Leigh syndrome
- Focal hypodense lesions
- Cortical and cerebellar atrophy
- White matter hyperintensity
- Basal ganglia involvement
- Agenesis/hypoplasia of the corpus callosum
Brain MR spectroscopy Abnormal accumulation of lactate in the parenchyma and cerebrospinal fluid
Laboratory investigation • Complete blood count
• Liver and renal functional tests
• Blood fasting glucose
• Blood gas analysis
• Plasma lactate levels
• Creatine phosphokinase (CPK)
• Plasma amino acids
• Urine amino and organic acids
• Redox status
• Acylcarnitine profiles
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and percentages. Multivariate regression models (Probit)
were used to compare patient subsets with and without
CVI. All tests were two-tailed, and P-values less than
0.05 were considered significant. Kaplan Meier curves
were used to compare survival between the two groups
(with and without CVI) and to show MACE-free survival
in CVI group. The STATA statistical software version
15 was used for all analyses.
Results
Genetic spectrum of PMD
The study enrolled 86 patients (30 males/56 females)
with established diagnosis of PMD. Mean age at diagno-
sis was 6.4 ± 8.6 years; in 3/83 patients (3.6%) the diagno-
sis was confirmed post-mortem. Muscular biopsy was
performed in 55 (64%) patients; of these, 27 showed
combined defects, with deficit in I-IV (11%) and I-III-IV
(11%) complexes being the most frequent [Table 2].
In 57 patients (66%) the diagnosis was confirmed by
molecular analysis [Table 2]. MELAS syndrome due to
MTTL1 A3243G mutation was the most frequent find-
ing (9%), followed by TMEM70 (6%), NARP and Barth
syndrome (5% each). Isolated mutations in subunits of
respiratory chain complexes were also documented, in
MTND6 (n = 2), MTND1 (n = 2) and MTND2, MTND3,
MTND5, MTCYB1, MT-CO1 or MT-TC (n = 1 for
each). Two patients were diagnosed with Kearns-Sayre
disease, one with Sengers syndrome. A child showed
clinical and genetic features consistent with Leber’s
hereditary optic neuropathy. Large mt-DNA depletion
not consistent with a specific syndrome was documented
in two children. Less common mutations were found in
POLG, ACAD9, SURF1, NDFUS1, SDHB, ELAC2,
DGUOK and TK2 genes. Finally, 6 nuclear mutations
(TIMMDC1, NUBPL, SFXN4, ATAD3A, SLC19A3,
DARS2) were identified through whole-exome
sequencing.
Extra-cardiac involvement
Neurologic manifestations were the dominating features
(52/86; 60%), mainly presenting with neurodevelopmen-
tal delay (36; 42%), epilepsy (28; 32.5%), hypo- or hyper-
tonia (17; 19.7%), recurrent headache/cerebral stroke (6;
7%) and/or neuro-radiological features consistent with
Leigh syndrome (5; 5.8%). No significant differences
were documented between cardiac and non-cardiac co-
horts (p 0.09). Other recurrent manifestations included
myopathy (32%) and ocular involvement (19%). Hearing
loss was documented in 8 patients, renal failure in 6 and
diabetes in 5 [Table 2].
Cardiovascular involvement
CVI was present in 31 patients (36%), with a significant
male prevalence (M/F: 1.8; p < 0.01) and a mean age at
onset of 5.7 ± 7.8 years (Table 1). In over one-third of
patients (12/31; 39%) early CVI could be documented in
the neonatal period (< 30 days); the onset of cardiomyop-
athy developed before 12 months of age in 14 children
(45%) and before 5 years in 24 (67,7%). In 58% (18/31)
ECG and/or echocardiographic abnormalities were iden-
tified in a pre-symptomatic phase, by routine screening
following PMD diagnosis. In two additional patients
(6%) cardiac hypertrophy was suspected prenatally, and
confirmed after birth. CVI constituted the first present-
ing sign of metabolic disease in 13 (42%) of patients:
heart failure was the most common clinical presentation
(6/31; 19%), followed by cardiac murmur at clinical
examination (5/31; 16%).
CVI was confirmed in all patients diagnosed with
TMEM70 deficiency and Barth syndrome; MELAS
syndrome was associated with heart disease in 62%
of the children and NARP in 25%. Among patients
with CI, mutations in ELAC2, NDUFS1, ACAD9,
tRNA (Glu), MT-ND1 and MT-ND3 were individu-
ally documented in one cardiac patient each (3.2%).
In addition one patient was diagnosed with Kearns
Sayre disease, one with Sengers syndrome and an-
other one presented with large mt-DNA deletion
(Table 1).
Cardioactive treatment was prescribed in 24 (77%) of
the 31 patients with CVI. Fourteen (45%) received beta-
blockers (propranolol or metoprolol); 10 (32%) required
chronic treatment with diuretics (furosemide and spir-
onolactone); 8 (26%) were treated with Ace-inhibitors
(captopril, enalapril), combined with angiotensin II re-
ceptor antagonists in two cases.
ECG findings
ECG abnormalities were documented in 23 of the 31
patients (74%), 95% of them showing abnormal echo
findings at first evaluation or through the follow-up. In
14 (45%) signs of ventricular hypertrophy were present
at baseline evaluation; right bundle branch block and
non-specific intra-ventricular delay were common
(22%). Three patients (10%) met the criteria for right
atrial enlargement (P pulmonale). Ventricular pre-
excitation was detected in 2 children (6%); first-degree
AV block, prolonged QTc interval and premature atrial
complexes were less common (1 patient each). During
follow-up, 2 patients developed premature ventricular
complexes with moderate prevalence (VPCs < 10,000/
day), which did not require medical treatment. Two pa-
tients developed complex ventricular arrhythmias, in-
cluding one requiring ICD implantation in primary
prevention. The child with Kearn-Sayre syndrome de-
veloped third degree AV block requiring permanent
pacing.
Brambilla et al. Orphanet Journal of Rare Diseases          (2020) 15:196 Page 4 of 12
Table 2 Clinical features, muscular biopsy, molecular diagnosis and outcome in enrolled patients
Overall Patients without CVI Patients with CVI p-value
Number of patients (%) 86 55 (64%) 31 (36%)
Males/Females 0.5 0.15 1.8 < 0.01
Mean age at diagnosis (years; ±SDS) 6.4 (±8.58) 7.8 (±10.08) 5.75 (±7.67) 0.3
Mean age at LFUP (years; ±SDS) 11.4 (±10.1) 11.8 (±9.17) 10.98 (±11.5) 0.7
Muscular biopsy (n° patients; %) 55 (63.9%) 37 (67.2%) 18 (58%) 0.4
Respiratory chain enzyme deficiency (n°;%) 49 (57%) 35 (63.6%) 14 (45%)
- Complex I 12 (14%) 9 (16.3%) 3 (9.7%) 0.7
- Complex II 1 (1.2%) 1 (1.8%) – 0.5
- Complex III 2 (2.3%) 2 (3.6%) – 0.4
- Complex IV 3 (3.5%) 2 (3.6%) 1 (3.2%) 0.8
- Complex V 4 (4.6%) 2 (3.6%) 2 (6.4%) 0.3
- Combined deficiencies 27 (31.4%) 19 (34.5%) 8 (25.8%) 0.8
Molecular analysis (n°;%) 57 (66.3%) 31 (56.3%) 26 (83.8%)
- MTTL1 (A3243G) 8 (9.3%) 3 (5.4%) 5 (16.1%) 0.4
- TMEM70 5 (5.8%) – 5 (16.1%) < 0.01
- NARP 4 (4.6%) 3 (5.4%) 1 (3.2%) 0.4
- Barth syndrome 4 (4.6%) – 4 (12.9%) 0.02
- POLG 2 (2.3%) 2 (3.6%) – 0.4
- ACAD9 2 (2.3%) 1 (1.8%) 1 (3.2%) 0.4
- SURF1 1 (1.2%) 1 (1.8%) – 0.4
- NDFUS1 1 (1.2%) – 1 (3.2%) 0.8
- SDHB 1 (1.2%) 1 (1.8%) – 0.4
- ELAC2 1 (1.2%) – 1 (3.2%) 0.4
- DGUOK 1 (1.2%) 1 (1.8%) – 0.4
- TK2 1 (1.2%) 1 (1.8%) – 0.4
- tRNA (Glu) 1 (1.2%) – 1 (1.2%) 0.4
- NAHD dehydrogenase (complex I) subunits: 7 (8.1%) 5 (9%) 2 (6.5%) 0.07
o MTND1 2 (2.3%) 1 (1.8%) 1 (3.2%)
o MTND2 1 (1.2%) 1 (1.8%) –
o MTND3 1 (1.2%) – 1 (3.2%)
o MTND5 1 (1.2%) 1 (1.8%) –
o MTND6 2 (2.3%) 2 (3.6%) –
- MTCYB1 1 (1.2%) 1 (1.8%) – 0.4
- MT-CO1 1 (1.2%) 1 (1.8%) – 0.4
- MT-TC 1 (1.2%) 1 (1.8%) – 0.4
- Leber’s hereditary optic neuropathy 1 (1.2%) 1 (1.8%) – 0.4
- Kearns-Sayre disease 2 (2.3%) 1 (1.8%) 1 (3.2%) 0.8
- Sengers disease 1 (1.2%) – 1 (3.2%) 0.2
- Large mt-DNA depletion 2 (2.3%) 1 (1.8%) 1 (3.2%) 0.8
- TIMMDC1 1 (1.2%) 1 (1.8%) – 0.4
- NUBPL 1 (1.2%) 1 (1.8%) – 0.4
- SFXN4 1 (1.2%) 1 (1.8%) – 0.4
- ATAD3A 1 (1.2%) – 1 (3.2%) 0.2
- DARS2 1 (1.2%) 1 (1.8%) – 0.4
- SLC19A3 1 (1.2%) – 1 (3.2%) 0.2
Extra-cardiac manifestations (n°; %)
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Table 2 Clinical features, muscular biopsy, molecular diagnosis and outcome in enrolled patients (Continued)
Overall Patients without CVI Patients with CVI p-value
- Failure to thrive 28 (32.5%) 12 (21.8%) 16 (51%) 0.1
- Neurologic 52 (60.4%) 33 (60%) 19 (52.7%) 0.9
o neurodevelopmental delay 36 (42%) 21 (38%) 15 (48%) –
o epilepsy 28 (32.5%) 14 (25.5%) 4 (13%) –
o hypo- or hypertonia 17 (19.7%) 7 (12.7%) 10 (32%) –
o recurrent headache/cerebral stroke 6 (7%) 3 (5.5%) 3 (9.7%) -
-
- Ocular 16 (18.6%) 6 (11%) 10 (32%) 0.1
- Hearing loss 8 (9.3%) 2 (3.6%) 6 (19.3%) 0.3
- Diabetes 5 (5.8%) 1 (1.8%) 4 (13%) 0.1
- Renal failure 6 (7%) 1 (1.8%) −5 (16%) 0.04
Cardiac involvement 31 (36%) – 31 (100%) n.a.
Clinical presentation
- Asymptomatic 18 (58%)
- Cardiac murmur 5 (16%)
- Heart failure 6 (19.3%)
- Prenatal suspicion 2 (6.4%)
- Systemic hypertension 3 (9.7%)
Baseline electrocardiographic anomalies (n°;%) 23 (74.1%) n.a.
- Atrial enlargement 3 (9.6%)
- LV hypertrophy/volume overload 14 (45%)
- Right bundle branch block 7 (22.5%)
- Ventricular pre-excitation 2 (6.4%)
- Increased QTc interval 1 (1.8%)
- Premature atrial complexes 1 (1.8%)
Baseline echocardiographic findings (n°;%)
- HCM 13 (42%)
- HCM/NC 4 (13%)
- DCM 8 (25.8%)
- PAH 4 (13%)
Major cardiac events (n°; %) 6 (19%)
- Hospitalization due to HF 2 (6.4%)
- Decease due to HF 2 (6.4%)
- Resuscitated cardiac arrest 1 (1.8%)
- PM implantation (high-grade AV block) 1 (2.8%)
- Sudden cardiac death 1 (1.8%) n.a.
Mortality 26 (30.2%) 12 (21.8%) 14 (45.1%) < 0.01
- Cardiac cause 3 (9.6%)
- Respiratory infection 2 (6.4%)
- Metabolic crisis 2 (6.4%)
- Stroke 1 (1.8%)
- Not assessed 6 (19%)
Abbreviations: CVI cardiovascular involvement; LFUP last follow-up; LV left ventricle; HCM hypertrophic cardiomyopathy; NC non-compaction; DCM
dilative cardiomyopathy; PAH pulmonary hypertension; HF heart failure; PM pace-maker; AV atrioventricular
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Echocardiographic findings
Hypertrophic cardiomyopathy was the most common
phenotype (17/31; 58%); mainly in a non-obstructive
form [Fig. 1]; dynamic obstruction was detected in a
single patient affected by MELAS syndrome. Hyper-
trophy was concentric in 14 of the 17 patients, ex-
tending to the right ventricle in two. Asymmetric
hypertrophy limited to interventricular septum was
considerably less common (3/17; 17%). Notably, a
mixed phenotype with aspects of ventricular non-
compaction (HCM/NC) occurred in 4 children (24%).
In 7 (23%) the phenotype was dilated cardiomyopathy;
one additional patient presented with mild diastolic
dysfunction and dilatation of the ascending aorta.
Four patients (13%) presented with pulmonary artery
hypertension. Arterial hypertension was documented
at 24-h monitoring in 3 patients (10%).
Long-term course and mortality
Mean follow-up duration was 5.4 ± 4.3 years. Stable
echocardiographic parameters (parietal and septal thick-
ness, chamber volumes and biventricular contractility)
were observed in most patients with CVI (14/17; 82%).
However, compared to the group with normal cardiac
findings, patients with CVI showed significantly worse
prognosis (p < 0.01) [Fig. 2]: all-cause mortality was 45%
(14/31) in the CVI versus 22% (12/55) in the non-CVI
group. Mean age at death was 6.7 ± 8.2 years and 6.6 ±
5.7 years respectively (p = 0.8).
Major adverse cardiac events were recorded in six pa-
tients (6/31; 19%), including death due to end-stage
heart failure (n = 2), sudden death due to ventricular
fibrillation (n = 1), hospitalization due to acute heart fail-
ure (n = 2) and high-grade ventricular block requiring
pace-maker implantation (n = 1).
Among the children presenting with HCM phenotype,
adverse remodeling with evolution towards dilated
phenotype was documented in a single patient diagnosed
with ELAC2 mutation [Fig. 3]. The clinical course was
complicated with sustained ventricular arrhythmias re-
quiring ICD implantation. He was put on a cardiac
transplantation list; however, he died shortly after due to
recurrent ventricular fibrillation, despite appropriate
ICD interventions. A second patient with Complex I de-
ficiency and mixed HCM/NC cardiomyopathy developed
progressive LV impairment and died due to refractory
heart failure. Moderate depression in LVEF (40%) was
recognized in a MELAS patient in the course of pneu-
monia; the child died within few weeks due to respira-
tory failure.
Among the 7 children with a dilative phenotype, 4
only had mild and stable LV dysfunction (FE 45–50%).
Two children diagnosed with Barth syndrome showed a
satisfactory recovery in LV function (EF from 25 to 50%)
after cardioactive (ace-inhibitors, beta-blockers). Pro-
gressive systolic impairment was documented in a single
patient with Senger syndrome; despite maximized
pharmacologic treatment, the child died due to refrac-
tory heart failure.
Fig. 1 Hypertrophic cardiomyopathy with non-obstructive, concentric phenotype in a 6-month old female diagnosed with TMEM70 deficiency
(Panel a: parasternal long-axis view, Panel b: sub-costal view); and in a 5-year old male with combined respiratory chain enzyme deficiencies
(complex I-III-IV): Panel c (long-axis view) and d (parasternal short-axis view). All images are in diastolic phase
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Three of the 4 patients developing pulmonary hyper-
tension died during follow-up: they were affected by
MELAS, TMEM70 and tRNAGlu mutation.
Non-cardiac cause of death were registered in 6 pa-
tients; 3 died due to acute respiratory infection (2 diag-
nosed with MELAS, 1 with tRNAGlu mutation), 2
patients due to acute metabolic crisis, embodying the
end-stage of the disease (MT-ND3) or exacerbated by
infection (TMEM70); one patient (7.1%) affected by
MELAS syndrome died as complication of cerebral
stroke.
Predictors of outcome
Early age at onset of cardiovascular symptoms was
associated with adverse prognosis and premature death
(p = 0.01). Age at presentation of CVI < 5 years consti-
tuted a negative predictor of outcome (p = 0.02); of note,
each month delay in clinical onset was associated to a
Fig. 2 Kaplan Meier survival analysis (a) showing impaired survival (due to all-cause mortality) in patients with cardiovascular involvement (red
line) and without CVI involvement (blue line) (p < 0.01). Time zero is defined as time at diagnosis of metabolic disorder. The bends display the
95% confidence interval (CI). A second curve (b) concerning MACE-free survival limited to the subgroup of CVI patients is reported in the bottom
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2% reduction in the risk of mortality during childhood
(p < 0.01). Finally, clinical onset characterized by acute
heart failure led to an increased mortality risk (p = 0.04),
irrespective of the age at presentation. Despite being
more common in males, females exhibited a worse out-
come with higher mortality rate (p 0.03). No gender-
related differences were documented in terms of age at
presentation (p = 0.2) of prevalence of heart failure at
presentation (p = 0.6).
Discussion
We investigated clinical profile and outcome of CVI in a
cohort of 86 paediatric patients diagnosed with primary
mitochondrial disorder. CVI was observed in 36% of our
cohort, mainly in the form of hypertrophic, non-
compaction or dilated cardiomyopathies and pulmonary
hypertension. TMEM70 and Barth syndrome were sys-
tematically associated with CVI, but prevalence also
proved high in MELAS syndrome. CVI was the
presenting manifestation of the underlying metabolic
disease in more than 40% of patients. Notably, we found
a higher prevalence of early CVI than previous findings
[5, 6, 12–14]: almost 40% of our children were diagnosed
with cardiovascular disease within the first month of life
(prenatally in 2 instances), half of them detected in a
pre-symptomatic phase. Such high prevalence may have
been elicited by the availability of a highly specialized
centre for metabolic disorders, triggering early referral.
A timely diagnosis of PDM-related cardiovascular dis-
ease, especially in a pre-symptomatic phase, has relevant
prognostic implications. Patients developing CVI exhib-
ited a > 2-fold higher mortality rate compared to the
counterpart without CVI (45% vs 22% respectively). Fe-
males, patients with diagnosis < 5 years and those with
heart failure symptoms at presentation were at greatest
risk. All these features identify individuals requiring ag-
gressive surveillance and management of cardiovascular
complications. In contrast with the relatively low
Fig. 3 ECG end echocardiogram from a 16-year old patient diagnosed with ELAC2 mutation. Initial phenotype with mild, concentric left
ventricular hypertrophy (Panels a-b) evolving to an intermediate (Panels c-d) and severe dilated/hypokinetic stage (Panels e-f)
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prevalence of events in adults with PMD [15], MACEs
were common in our children, occurring in almost 20%.
Both heart failure-related and arrhythmic deaths
occurred; among non lethal events, acute heart failure
and advanced AV blocks represented treatable
complications.
Our findings are in agreement with prior reports
highlighting the adverse prognostic role of PMD-related
CVI, suggesting a particularly unfavourable outcome in
paediatric cohorts [6, 14, 16, 17]. The present study sup-
ports the view that CVI may act as the main driver of
adverse outcome in PMD, rather than simply represent-
ing a marker of more aggressive multi-organ disease.
Yet, it is difficult and probably wrong to generalize such
conclusion to all PMD patients, given their vast and het-
erogeneous genetic spectrum. For example, the prognos-
tic role of CVI appeared to be particularly relevant in
distinct PMD syndrome, as ELAC2 and Sengers syn-
drome, in which refractory heart failure and arrhythmic
act as primary cause of demise, independent of the de-
gree of extra-cardiac involvement. This is in line with
published case series [18–20], suggesting the opportun-
ity of intensive treatment in this subset, including ven-
tricular mechanical assistance and heart transplantation.
However, in other settings such as MELAS syndrome
[8], patients presenting with CVI were globally more
compromised, and heart disease seemed to represent a
hallmark of phenotype severity rather than the primary
cause of demise. This paradigm also seems to apply to
TMEM70 deficiency, in which heart involvement is a
constant feature but per se a stable one; acute decom-
pensation may develop as consequence of metabolic cri-
sis or severe infections [21]. Prompt treatment of
metabolic crisis, appropriate nutrition with avoidance of
fasting and prevention of infections (i.e. vaccination)
represent the best “cardiac” preventive measures in these
children. Likewise, in patients with Barth syndrome, sur-
vival rates have dramatically changed after the introduc-
tion of cardioactive treatment as well as prophylaxis for
infections [22, 23] and stable recovery of LV function
was observed in our cohort. Thus, individualized assess-
ment and follow-up strategies based on genotype may
represent the future in PMD case.
Mitochondrial disorders may be transmitted either as
Mendelian trait or follow a matrilineal inheritance pat-
tern; therefore, except for X-linked disorders (i.e. Barth
syndrome), no gender prevalence is expected. As elem-
ent of interest, we reported higher prevalence of CVI in
males, but worse outcome in females (p = 0.03), similar
to what has been reported for sarcomeric HCM in adult
patients [24]. Whether and to what extent this gender
bias entails social, as well as genetic, causes remains un-
clear. In our experience, poor social status and levels of
educations are associated with delay in the identification
of signs of infection, inadequate feeding and cardiac and
metabolic decompensation in children, representing ur-
gent unmet needs in paediatric healthcare.
Our data are consistent with previous literature
reporting complex I deficiency as one of the most com-
mon enzyme defect in childhood mitochondrial
disorders, without significant differences between the
two groups of patients. The molecular basis of this
phenomenon is difficult to assess, possibly related to its
dual genetic control (nuclear and mtDNA) and to the
fact that it is the largest complex in the mitochondrial
respiratory chain. The clinical spectrum of complex I
deficiency is heterogeneous but the majority of affected
individuals show an early-onset, rapidly progressive
disease, occurring with severe lactic acidosis, Leigh syn-
drome, leukoencephalopathy, hepatopathy and/or car-
diomyopathy [25–27].
Treatment options in PMD patients remain limited.
Shared protocols for pharmacologic treatment of paedi-
atric cardiomyopathies and paediatric heart failure are
not yet available; so far, current treatment strategies are
commonly derived from adult guidelines and/or rely on
the experiences of single centres. Non-pharmacologic
options as mechanical ventricular assistance devices or
heart transplantation are often considered unsuitable for
patients affected by mitochondrial disorders, due to the
concomitant presence of severe multi-organ involve-
ment; however, this may not always be the case and the
field deserves appropriate investigation. Heart trans-
plantation is feasible, but candidate selection remains
very challenging [28–32].
Limitations
The present study has been conducted as retrospective
research. Certain information as biochemical markers
(NT-ProBNP, Troponins), mt-DNA heteroplasmy or in-
strumental data (systematic evaluation of diastolic func-
tion, cardiac magnetic resonance) were not available in
all patients, despite systematic implementation of diag-
nostic protocols over the years. We could not assess a
significant correlation between distinct pathogenic mu-
tations, specific respiratory chain enzyme deficiency or
echocardiographic phenotype and cardiac outcome; the-
ses result may be partially explained by the heterogeneity
of molecular diagnosis in our paediatric cohort and con-
sequent small number of patients per molecular diagno-
sis, affecting statistical power. Larger studies base on
international consortia are needed to confront this issue.
Finally, the absence of standard treatment protocols for
the management of PMD-related cardiac disorders, as
well as concomitant metabolic treatment, did not allow
a reliable estimate of therapeutic efficacy in our PMD
patients.
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Conclusions
Cardiovascular involvement is a common feature of pri-
mary mitochondrial disorders and occurs earlier than
previously described, across the PMD paediatric
spectrum. CVI is associated with unfavourable prognosis
and major adverse cardiac events are not rare in affected
patients; however, there is ample variability reflecting
the diverse genetic substrates. Female sex, acute heart
failure and age at onset < 5 years are the main predictors
of outcome associated with CVI. Cardiac assessment is
strongly recommended in all patients with confirmed or
suspected PMD, even if asymptomatic at the time of
diagnosis, and regular cardiac follow-up is required.
Moreover, our data suggest the need for tailored man-
agement of heart failure and sudden death prevention in
children with PMD.
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